Glioblastoma (GBM), the most common and aggressive primary malignant brain tumor in adults, continues to have a poor prognosis despite decades of advances in surgery, radiotherapy, and chemotherapy. Even with current standard treatment, patients typically survive only 14–15 months after diagnosis.
One of the greatest obstacles is the blood–brain barrier (BBB), which prevents the vast majority of drugs from reaching tumor tissue at therapeutic concentrations. While the tumor core may exhibit regions of increased vascular permeability, infiltrative tumor margins often retain an intact BBB, resulting in uneven drug distribution, treatment resistance, and tumor recurrence. To mitigate this treatment gap, recent research has focused on the use of nanomaterial-based drug delivery to increase treatment efficacy by facilitating drug delivery across the BBB.
A comprehensive review published in Volume 12 of the Chinese Neurosurgical Journal on July 01, 2026, explores the latest generation of BBB-aware nanotherapeutic platforms designed to transport drugs across the BBB and the closely related blood–brain tumor barrier (BBTB), enabling more precise and effective treatment of GBM. The collaborative study was led by Dr. Xueqiong Su from Beijing University of Technology, Professor Yujun Song from University of Science and Technology Beijing, and Dr. Hao Wang from Capital Medical University. "Our review outlines the clinical challenges in GBM therapy and examines how targeted, stimuli-responsive, biomimetic nanomedicines overcome these obstacles to improve treatment outcomes," explained Prof. Song.
Unlike conventional chemotherapy, nanomedicines can be engineered to improve drug stability, extend circulation time, protect fragile therapeutic molecules, and release their cargo selectively within tumors. The review discusses a broad range of nanocarriers, including lipid-based nanoparticles, polymeric nanoparticles, dendrimers, inorganic nanomaterials, and biomimetic systems that imitate natural cells or lipoproteins to evade immune detection and improve brain targeting.
The authors describe several complementary strategies for overcoming the BBB. Passive targeting exploits the enhanced permeability and retention (EPR) effect, while active targeting equips nanoparticles with ligands that recognize receptors highly expressed on BBB endothelial cells or glioblastoma cells, such as transferrin receptors, low-density lipoprotein receptor-related protein (LRP1), different nutrient transporters, and tumor cell markers. These approaches improve nanoparticle transport into the brain and increase drug accumulation within tumors.
Another major focus of the review is stimuli-responsive nanomedicine. These smart delivery systems remain stable during circulation but release their therapeutic payload only when exposed to specific internal conditions, such as acidic pH or elevated oxidative stress, or external triggers including near-infrared light, magnetic fields, ultrasound, and heat. Such spatiotemporal control maximizes tumor-specific cytotoxicity and minimizes off-target effects on surrounding healthy brain tissue.
Beyond drug delivery, nanoparticles are increasingly being designed to perform multiple therapeutic functions simultaneously. Some generate localized heat through magnetic hyperthermia or photothermal therapy, while others produce reactive oxygen species for photodynamic or sonodynamic therapy. Several platforms can also deliver nucleic-acid therapeutics, expanding treatment options beyond conventional chemotherapy.
The review also highlights encouraging early clinical progress. Technologies, such as NanoTherm®, an iron oxide-based magnetic hyperthermia system, and NU-0129, a gold nanoparticle-based RNA interference therapy capable of crossing the human BBB, demonstrate that advanced nanomedicines are beginning to translate from laboratory research into clinical testing.
The authors also emphasize the challenges. "Long-term safety, scalable manufacturing, regulatory approval, and consistent performance across patients must all be addressed before nanomedicine becomes a routine component of glioblastoma treatment," explained Dr. Wang.
The review study also discusses emerging opportunities, including biomimetic delivery systems, multifunctional nanoparticles, and artificial intelligence-assisted nanomaterial design, which could accelerate the development of more personalized therapies.
Overall, the study presents BBB-aware nanomedicine as one of the most promising strategies for overcoming one of neuro-oncology's greatest therapeutic barriers. By combining targeted drug delivery with intelligent, stimuli-responsive technologies, these next-generation platforms could reshape the treatment landscape for patients with glioblastoma.
